Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2876Carcinoma, Non-Small-Cell Lung 2430Breast Neoplasms 2070Colorectal Neoplasms 1248Neoplasm Metastasis 1233Prostatic Neoplasms 1083Melanoma 973Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 851Leukemia, Myeloid, Acute 809Lung Neoplasms 759Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 624Carcinoma, Hepatocellular 567Carcinoma, Renal Cell 547Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 469Head and Neck Neoplasms 452Glioblastoma 436Advanced Solid Tumors 433Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Castrate Resistant Prostate Cancer (CRPC) × Clear all
NCT00868595 2019-10-08

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Bellicum Pharmaceuticals

Phase 1 Completed
18 enrolled
Genitourinary

Castrate Resistant Prostate Cancer (CRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡